ID   PER2_RAT                Reviewed;        1257 AA.
AC   Q9Z301;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   24-JUL-2024, entry version 161.
DE   RecName: Full=Period circadian protein homolog 2;
DE            Short=rPER2;
DE   AltName: Full=Circadian clock protein PERIOD 2;
GN   Name=Per2 {ECO:0000312|RGD:61945};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:BAA34187.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INDUCTION.
RC   STRAIN=Sprague-Dawley {ECO:0000312|EMBL:BAA34187.1};
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA34187.1};
RX   PubMed=9765215; DOI=10.1074/jbc.273.42.27039;
RA   Sakamoto K., Nagase T., Fukui H., Horikawa K., Okada T., Tanaka H.,
RA   Sato K., Miyake Y., Ohara O., Kako K., Ishida N.;
RT   "Multitissue circadian expression of rat period homologue (rPer2) mRNA is
RT   governed by the mammalian circadian clock, the suprachiasmatic nucleus in
RT   the brain.";
RL   J. Biol. Chem. 273:27039-27042(1998).
RN   [2] {ECO:0000305}
RP   INTERACTION WITH TIMELESS.
RX   PubMed=11112428; DOI=10.1006/bbrc.2000.3927;
RA   Sakamoto S., Miyazaki K., Fukui H., Oishi K., Hayasaka N., Okada M.,
RA   Kamakura M., Taniguchi T., Nagai K., Ishida N.;
RT   "Molecular characterization and nuclear localization of rat timeless-like
RT   gene product.";
RL   Biochem. Biophys. Res. Commun. 279:131-138(2000).
RN   [3]
RP   INTERACTION WITH CRY1, CRY BINDING DOMAIN, NUCLEAR LOCALIZATION SIGNAL, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11533252; DOI=10.1128/mcb.21.19.6651-6659.2001;
RA   Miyazaki K., Mesaki M., Ishida N.;
RT   "Nuclear entry mechanism of rat PER2 (rPER2): role of rPER2 in nuclear
RT   localization of CRY protein.";
RL   Mol. Cell. Biol. 21:6651-6659(2001).
RN   [4] {ECO:0000305}
RP   TISSUE SPECIFICITY.
RX   PubMed=12710990; DOI=10.1016/s0306-4522(03)00004-6;
RA   Shieh K.-R.;
RT   "Distribution of the rhythm-related genes rPERIOD1, rPERIOD2, and rCLOCK,
RT   in the rat brain.";
RL   Neuroscience 118:831-843(2003).
RN   [5]
RP   FUNCTION.
RX   PubMed=14672706; DOI=10.1016/j.bbrc.2003.11.099;
RA   Kawamoto T., Noshiro M., Sato F., Maemura K., Takeda N., Nagai R.,
RA   Iwata T., Fujimoto K., Furukawa M., Miyazaki K., Honma S., Honma K.I.,
RA   Kato Y.;
RT   "A novel autofeedback loop of Dec1 transcription involved in circadian
RT   rhythm regulation.";
RL   Biochem. Biophys. Res. Commun. 313:117-124(2004).
RN   [6] {ECO:0000305}
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=15094047; DOI=10.1016/s0014-5793(04)00322-9;
RA   Muehlbauer E., Wolgast S., Finckh U., Peschke D., Peschke E.;
RT   "Indication of circadian oscillations in the rat pancreas.";
RL   FEBS Lett. 564:91-96(2004).
RN   [7]
RP   INTERACTION WITH BTRC AND FBXW11, AND MUTAGENESIS OF 93-SER--SER-97 AND
RP   478-SER--SER-482.
RX   PubMed=18782782; DOI=10.1093/jb/mvn112;
RA   Ohsaki K., Oishi K., Kozono Y., Nakayama K., Nakayama K.I., Ishida N.;
RT   "The role of {beta}-TrCP1 and {beta}-TrCP2 in circadian rhythm generation
RT   by mediating degradation of clock protein PER2.";
RL   J. Biochem. 144:609-618(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-693 AND SER-697, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Transcriptional repressor which forms a core component of the
CC       circadian clock. The circadian clock, an internal time-keeping system,
CC       regulates various physiological processes through the generation of
CC       approximately 24 hour circadian rhythms in gene expression, which are
CC       translated into rhythms in metabolism and behavior. It is derived from
CC       the Latin roots 'circa' (about) and 'diem' (day) and acts as an
CC       important regulator of a wide array of physiological functions
CC       including metabolism, sleep, body temperature, blood pressure,
CC       endocrine, immune, cardiovascular, and renal function. Consists of two
CC       major components: the central clock, residing in the suprachiasmatic
CC       nucleus (SCN) of the brain, and the peripheral clocks that are present
CC       in nearly every tissue and organ system. Both the central and
CC       peripheral clocks can be reset by environmental cues, also known as
CC       Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the
CC       central clock is light, which is sensed by retina and signals directly
CC       to the SCN. The central clock entrains the peripheral clocks through
CC       neuronal and hormonal signals, body temperature and feeding-related
CC       cues, aligning all clocks with the external light/dark cycle. Circadian
CC       rhythms allow an organism to achieve temporal homeostasis with its
CC       environment at the molecular level by regulating gene expression to
CC       create a peak of protein expression once every 24 hours to control when
CC       a particular physiological process is most active with respect to the
CC       solar day. Transcription and translation of core clock components
CC       (CLOCK, NPAS2, BMAL1, BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a
CC       critical role in rhythm generation, whereas delays imposed by post-
CC       translational modifications (PTMs) are important for determining the
CC       period (tau) of the rhythms (tau refers to the period of a rhythm and
CC       is the length, in time, of one complete cycle). A diurnal rhythm is
CC       synchronized with the day/night cycle, while the ultradian and
CC       infradian rhythms have a period shorter and longer than 24 hours,
CC       respectively. Disruptions in the circadian rhythms contribute to the
CC       pathology of cardiovascular diseases, cancer, metabolic syndrome and
CC       aging. A transcription/translation feedback loop (TTFL) forms the core
CC       of the molecular circadian clock mechanism. Transcription factors,
CC       CLOCK or NPAS2 and BMAL1 or BMAL2, form the positive limb of the
CC       feedback loop, act in the form of a heterodimer and activate the
CC       transcription of core clock genes and clock-controlled genes (involved
CC       in key metabolic processes), harboring E-box elements (5'-CACGTG-3')
CC       within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which
CC       are transcriptional repressors form the negative limb of the feedback
CC       loop and interact with the CLOCK|NPAS2-BMAL1|BMAL2 heterodimer
CC       inhibiting its activity and thereby negatively regulating their own
CC       expression. This heterodimer also activates nuclear receptors NR1D1/2
CC       and RORA/B/G, which form a second feedback loop and which activate and
CC       repress BMAL1 transcription, respectively. PER1 and PER2 proteins
CC       transport CRY1 and CRY2 into the nucleus with appropriate circadian
CC       timing, but also contribute directly to repression of clock-controlled
CC       target genes through interaction with several classes of RNA-binding
CC       proteins, helicases and others transcriptional repressors. PER appears
CC       to regulate circadian control of transcription by at least three
CC       different modes. First, interacts directly with the CLOCK-BMAL1 at the
CC       tail end of the nascent transcript peak to recruit complexes containing
CC       the SIN3-HDAC that remodel chromatin to repress transcription. Second,
CC       brings H3K9 methyltransferases such as SUV39H1 and SUV39H2 to the E-box
CC       elements of the circadian target genes, like PER2 itself or PER1. The
CC       recruitment of each repressive modifier to the DNA seems to be very
CC       precisely temporally orchestrated by the large PER complex, the
CC       deacetylases acting before than the methyltransferases. Additionally,
CC       large PER complexes are also recruited to the target genes 3'
CC       termination site through interactions with RNA-binding proteins and
CC       helicases that may play a role in transcription termination to regulate
CC       transcription independently of CLOCK-BMAL1 interactions. Recruitment of
CC       large PER complexes to the elongating polymerase at PER and CRY
CC       termination sites inhibited SETX action, impeding RNA polymerase II
CC       release and thereby repressing transcriptional reinitiation. May
CC       propagate clock information to metabolic pathways via the interaction
CC       with nuclear receptors. Coactivator of PPARA and corepressor of NR1D1,
CC       binds rhythmically at the promoter of nuclear receptors target genes
CC       like BMAL1 or G6PC1. Directly and specifically represses PPARG
CC       proadipogenic activity by blocking PPARG recruitment to target
CC       promoters and thereby transcriptional activation. Required for fatty
CC       acid and lipid metabolism, is involved as well in the regulation of
CC       circulating insulin levels. Plays an important role in the maintenance
CC       of cardiovascular functions through the regulation of NO and
CC       vasodilatatory prostaglandins production in aortas. Controls circadian
CC       glutamate uptake in synaptic vesicles through the regulation of VGLUT1
CC       expression. May also be involved in the regulation of inflammatory
CC       processes. Represses the CLOCK-BMAL1 induced transcription of
CC       BHLHE40/DEC1 and ATF4. Negatively regulates the formation of the
CC       TIMELESS-CRY1 complex by competing with TIMELESS for binding to CRY1.
CC       {ECO:0000269|PubMed:14672706}.
CC   -!- SUBUNIT: Homodimer. Component of the circadian core oscillator, which
CC       includes the CRY proteins, CLOCK or NPAS2, BMAL1 or BMAL2, CSNK1D
CC       and/or CSNK1E, TIMELESS, and the PER proteins. Interacts with CLOCK-
CC       BMAL1 (off DNA). Interacts directly with PER1 and PER3, and through a
CC       C-terminal domain, with CRY1 and CRY2. Interacts (via PAS 2 domain)
CC       with TIMELESS. Interacts with NFIL3. Different large complexes have
CC       been identified with different repressive functions. The core of PER
CC       complexes is composed of at least PER1, PER2, PER3, CRY1, CRY2, CSNK1D
CC       and/or CSNK1E. The large PER complex involved in the repression of
CC       transcriptional termination is composed of at least PER2, CDK9, DDX5,
CC       DHX9, NCBP1 and POLR2A (active). The large PER complex involved in the
CC       histone deacetylation is composed of at least HDAC1, PER2, SFPQ and
CC       SIN3A. The large PER complex involved in the histone methylation is
CC       composed of at least PER2, CBX3, TRIM28, SUV39H1 and/or SUV39H2; CBX3
CC       mediates the formation of the complex. Interacts with SETX; the
CC       interaction inhibits termination of circadian target genes. Interacts
CC       with the nuclear receptors HNF4A, NR1D1, NR4A2, RORA, PPARA, PPARG and
CC       THRA; the interaction with at least PPARG is ligand dependent.
CC       Interacts with PML. Interacts (phosphorylated) with BTRC and FBXW11;
CC       the interactions trigger proteasomal degradation. Interacts with NONO
CC       and SFPQ. Interacts with CAVIN3 (By similarity). Interacts with MAGEL2
CC       (By similarity). Interacts with MAP1LC3B (By similarity). Interacts
CC       with HNF4A (By similarity). {ECO:0000250|UniProtKB:O15055,
CC       ECO:0000250|UniProtKB:O54943, ECO:0000269|PubMed:11112428,
CC       ECO:0000269|PubMed:11533252, ECO:0000269|PubMed:18782782}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11533252}. Cytoplasm
CC       {ECO:0000269|PubMed:11533252}. Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:O54943}. Note=Nucleocytoplasmic shuttling is
CC       effected by interaction with other circadian core oscillator proteins
CC       and/or by phosphorylation. Translocate to the nucleus after
CC       phosphorylation by CSNK1D or CSNK1E. Also translocated to the nucleus
CC       by CRY1 or CRY2. PML regulates its nuclear localization (By
CC       similarity). {ECO:0000250|UniProtKB:O54943}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined including eye,
CC       brain, heart, lung, spleen, liver, pancreas and kidney. In the CNS,
CC       highly expressed in the SCN, internal granular layer of granular cells
CC       of the olfactory bulb, tuberculum olfactorium, piriform cortex, gyrus
CC       dentatus of the hippocampus, cerebellum, pars tuberalis/median
CC       eminence, and pituitary, and moderately in the tenia tecta, caudate
CC       putamen, accumbens nucleus, superior and inferior colliculus and pineal
CC       gland. {ECO:0000269|PubMed:12710990, ECO:0000269|PubMed:15094047,
CC       ECO:0000269|PubMed:9765215}.
CC   -!- INDUCTION: In eye, brain, heart, lung, spleen, liver, pancreas and
CC       kidney, expression exhibits a circadian rhythm in the presence of
CC       light/dark cycles. {ECO:0000269|PubMed:15094047,
CC       ECO:0000269|PubMed:9765215}.
CC   -!- PTM: Acetylated. Deacetylated by SIRT1, resulting in decreased protein
CC       stability. Deacetylated by SIRT6, preventing its degradation by the
CC       proteasome, resulting in increased protein stability.
CC       {ECO:0000250|UniProtKB:O54943}.
CC   -!- PTM: Phosphorylated by CSNK1E and CSNK1D. Phosphorylation results in
CC       PER2 protein degradation. May be dephosphorylated by PP1 (By
CC       similarity). {ECO:0000250|UniProtKB:O54943}.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation.
CC       Ubiquitination may be inhibited by CRY1.
CC       {ECO:0000250|UniProtKB:O54943}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB016532; BAA34187.1; -; mRNA.
DR   PIR; T13957; T13957.
DR   RefSeq; NP_113866.1; NM_031678.1.
DR   RefSeq; XP_006245538.1; XM_006245476.3.
DR   RefSeq; XP_017452107.1; XM_017596618.1.
DR   AlphaFoldDB; Q9Z301; -.
DR   SMR; Q9Z301; -.
DR   BioGRID; 248899; 2.
DR   CORUM; Q9Z301; -.
DR   STRING; 10116.ENSRNOP00000027507; -.
DR   iPTMnet; Q9Z301; -.
DR   PhosphoSitePlus; Q9Z301; -.
DR   PaxDb; 10116-ENSRNOP00000027507; -.
DR   Ensembl; ENSRNOT00000027506.6; ENSRNOP00000027507.4; ENSRNOG00000020254.8.
DR   Ensembl; ENSRNOT00055016243; ENSRNOP00055013051; ENSRNOG00055009603.
DR   Ensembl; ENSRNOT00060015508; ENSRNOP00060012104; ENSRNOG00060009201.
DR   GeneID; 63840; -.
DR   KEGG; rno:63840; -.
DR   AGR; RGD:61945; -.
DR   CTD; 8864; -.
DR   RGD; 61945; Per2.
DR   eggNOG; KOG3753; Eukaryota.
DR   GeneTree; ENSGT00940000156342; -.
DR   HOGENOM; CLU_006667_0_0_1; -.
DR   InParanoid; Q9Z301; -.
DR   OMA; ENCSMGR; -.
DR   OrthoDB; 2971905at2759; -.
DR   PhylomeDB; Q9Z301; -.
DR   TreeFam; TF318445; -.
DR   PRO; PR:Q9Z301; -.
DR   Proteomes; UP000002494; Chromosome 9.
DR   Bgee; ENSRNOG00000020254; Expressed in skeletal muscle tissue and 19 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0042826; F:histone deacetylase binding; ISO:RGD.
DR   GO; GO:1990226; F:histone methyltransferase binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0019900; F:kinase binding; ISO:RGD.
DR   GO; GO:0016922; F:nuclear receptor binding; ISO:RGD.
DR   GO; GO:0036002; F:pre-mRNA binding; ISO:RGD.
DR   GO; GO:0070063; F:RNA polymerase binding; ISO:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0001222; F:transcription corepressor binding; ISO:RGD.
DR   GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0097167; P:circadian regulation of translation; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEP:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; IBA:GO_Central.
DR   GO; GO:0006631; P:fatty acid metabolic process; ISS:UniProtKB.
DR   GO; GO:0006094; P:gluconeogenesis; ISS:UniProtKB.
DR   GO; GO:0005978; P:glycogen biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0019249; P:lactate biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0042754; P:negative regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0070345; P:negative regulation of fat cell proliferation; ISS:UniProtKB.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; ISS:UniProtKB.
DR   GO; GO:0060567; P:negative regulation of termination of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:2000678; P:negative regulation of transcription regulatory region DNA binding; ISS:UniProtKB.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0051946; P:regulation of glutamate uptake involved in transmission of nerve impulse; ISS:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0050767; P:regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0019229; P:regulation of vasoconstriction; ISS:UniProtKB.
DR   GO; GO:0002931; P:response to ischemia; ISS:UniProtKB.
DR   GO; GO:0050872; P:white fat cell differentiation; ISS:UniProtKB.
DR   CDD; cd00130; PAS; 1.
DR   Gene3D; 3.30.450.20; PAS domain; 2.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013655; PAS_fold_3.
DR   InterPro; IPR048814; Per1-3_PAS-A.
DR   InterPro; IPR022728; Period_circadian-like_C.
DR   InterPro; IPR050760; Period_circadian_regulator.
DR   PANTHER; PTHR11269; PERIOD CIRCADIAN PROTEIN; 1.
DR   PANTHER; PTHR11269:SF9; PERIOD CIRCADIAN PROTEIN HOMOLOG 2; 1.
DR   Pfam; PF08447; PAS_3; 1.
DR   Pfam; PF21353; Per3-like_PAS-A; 1.
DR   Pfam; PF12114; Period_C; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF55785; PYP-like sensor domain (PAS domain); 1.
DR   PROSITE; PS50112; PAS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Biological rhythms; Cytoplasm; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..1257
FT                   /note="Period circadian protein homolog 2"
FT                   /id="PRO_0000162632"
FT   DOMAIN          179..246
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          319..385
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          393..436
FT                   /note="PAC"
FT                   /evidence="ECO:0000255"
FT   REGION          1..59
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          471..567
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          478..482
FT                   /note="Important for protein stability"
FT                   /evidence="ECO:0000269|PubMed:18782782"
FT   REGION          510..709
FT                   /note="CSNK1E binding domain"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   REGION          678..706
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          757..833
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          882..1067
FT                   /note="Interaction with PPARG"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   REGION          993..1044
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1070..1108
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1157..1257
FT                   /note="CRY binding domain"
FT                   /evidence="ECO:0000269|PubMed:11533252"
FT   REGION          1226..1257
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           109..118
FT                   /note="Nuclear export signal 1"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOTIF           306..310
FT                   /note="LXXLL"
FT   MOTIF           460..469
FT                   /note="Nuclear export signal 2"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOTIF           778..794
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:11533252"
FT   MOTIF           983..990
FT                   /note="Nuclear export signal 3"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOTIF           1051..1055
FT                   /note="LXXLL"
FT   COMPBIAS        1..52
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        475..503
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        514..562
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        818..832
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        999..1019
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1237..1257
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         528
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         531
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         538
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         544
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         554
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         659
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O15055"
FT   MOD_RES         693
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         697
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         706
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         758
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         763
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         858
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         939
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         964
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         971
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MOD_RES         1126
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O54943"
FT   MUTAGEN         93..97
FT                   /note="SGCSS->IGCSI: No effect on interaction with BTRC and
FT                   FBXW11. Strongly decreases interaction with BTRC and FBXW11
FT                   and increases protein stability; when associated with 478-
FT                   N--N-482."
FT                   /evidence="ECO:0000269|PubMed:18782782"
FT   MUTAGEN         478..482
FT                   /note="SGYGS->NGYGN: Strongly decreases interaction with
FT                   BTRC and FBXW11 and increases protein stability. Strongly
FT                   decreases interaction with BTRC and FBXW11 and increases
FT                   protein stability; when associated with 93-I--I-97."
FT                   /evidence="ECO:0000269|PubMed:18782782"
SQ   SEQUENCE   1257 AA;  136028 MW;  A772E3C453E63CED CRC64;
     MNGYVDFSPS PTSPTQEPGE PQPTQAVLQE DVDMSSGSSG NENCSTGRDS QGSDCDDSGK
     ELRMLVESSN THPSPDDTFR LMMTEAEHNP STSGCSSEQS AKADAHKELI RTLRELKVHL
     PADKKAKGKA STLATLKYAL RSVKQVKANE EYYQLLMSSE SQPCSVDVPS YTMEQVEGIT
     SEYIVKNSDM FAVAVSLVSG KILYISNQVA PIFHCKKDAF SDAKFVEFLA PHDVSVFHSY
     TTPYKLPPWS VSSGLDSFTQ ECMEEKSFFC RVSVGKHHEN EIRYQPFRMT PYLVKVQEQK
     GAASQLCCLL LAERVHSGYE APRIPPEKRI FTTTHTPNCL FQDVDERAVP LLGYLPQDLI
     ETPVLVQLHP SDRPLMLAIH KKILQASGQP FDYSPIRFRT RNGEYITLDT SWSSFINPWS
     RKISFIIGRH KVRVGPLNED VFAASPCPEE KTPHPSVQEL TEQIHRLLMQ PVPHSGSSGY
     GSLGSNGSHE HLMSQTSSSD SNGQEESHWR RSGIFKTSGK SQSKSHFSPE SGGQKEASVA
     EMQSSPPAQV RSVTTMERDS SGASLPKASF PEELTYKSQP PCSYQQISCL DSVIRYLESC
     NEAATLKRKC EFPANIPSRK ATVSPGLHSG EAARSSKVTS HTEVSAHLSS LALPGKAESV
     VSLTSQCSYS STIVHVGDKK PQPELETVED VASGPESQDD AAGGLSQEKG SLQKLGLTKE
     VLAAHTQREE QGFLQRFREV SRLGALQAHC QNYLQERSRA PASDRGLRNA SGIESSWKKT
     GKNRKLKSKR VKTRDSSEST GSGGPVSHRP PLVGLNATAW SPSDTSQSSC PSAPFPAPVP
     AYPLPVFPAP GIVSTPGTVV APPAAAHTGF TMPVVPMGTQ PEFAVQPLPF AAPLAPVMAF
     MLPSYPFPPA TPNLPQAFFP SQPHFPAHPT LASEITPASQ AEFPSRTSML RQPCACPVTP
     PAGTVALGRA SPPLFQSRGS SPLQLNLLQL EEAPESSTGA AGTLGTTGTA ASGLDCTSGA
     SRDRQPKAPP TCSEPSDTQN SDAISTSSDL LNLLLGEDLC SATGSALSRS GASATSDSLG
     SSSLGCDTSR SGAGSSDTSH TSKYFGSIDS SENNHKAKMI TDTEESEQFI KYVLQDPIWL
     LMANTDDNIM MTYQLPSRDL QAVLKEDQEK LKLLQRSQPH FTEGQRRELR EVHPWVHTGG
     LPTAIDVTGC VYCESEEKGN LCLPYEEDSP SLGLCDTSEA KEEESGQLAN PRKEAQT
//
